

## Northern (NHS) Treatment Advisory Group

### Treatment Appraisal: Decision Summary

Date	2 <sup>nd</sup> June 2015
Appraisal & Details	<p><b>OmniPod® (Ypsomed UK) continuous subcutaneous insulin infusion pump system (medical device)</b></p> <p>The NHS Northern Treatment Advisory Group was requested by a member organisation to conduct a re-appraisal of, and issue a recommendation for, the use of the OmniPod® insulin infusion system.</p>
Recommendation	<p><b>The Northern (NHS) Treatment Advisory Group recommends the use of the Omnipod® insulin infusion system as an option for <u>new patients</u> in whom insulin pump therapy is recommended. i.e. as outlined in the <a href="#">NICE TA</a>.</b></p> <p>The group was satisfied that the Omnipod® insulin infusion system demonstrates consistent insulin delivery compared to other continuous subcutaneous insulin infusions (CSII) systems. The group also noted that the changes in commissioning arrangements since the previous recommendation in 2011 meant that those patients who are under 19 and attend a paediatric specialist pump clinic at the two specialist centres will now be offered a choice of all CSII systems. It was agreed that this practice should be adopted across the NTAG region for all patients.</p> <p>This recommendation applies to new patients only.</p> <p>Patients who are already using an insulin pump system can be offered the choice of an Omnipod® system only when they are approaching the end of their 4 year pump lifecycle. This is to minimise wastage.</p>
Clinical evidence summary	Clinical advantages have only been demonstrated in low quality studies and are limited to demonstrating more consistent insulin delivery and small improvements in glycaemic control compared with other CSII systems.
Safety	No safety concerns were raised within in the limited data available.
Patient Perspective	The OmniPod system is an innovative wireless pod system that may permit greater physical freedom and reduced psychological effects on image self-awareness compared with conventional systems. If suitable, patients are likely to prefer omnipod over other CSII systems.
Cost analysis summary	CSII systems are costly at about £2,000 to £3,000 per patient per annum. The mean annual cost of the OmniPod system is higher than other CSII systems. However accurate cost estimations are confounded by differences in the costs and rates of use of system consumables where the majority of costs lie. In addition the OmniPod system can hold up to 200 units of insulin per pod. Therefore patients with particularly high insulin requirements (i.e. > 200 units per three days) will use a greater number of pods than estimated and mean annual costs will increase accordingly. Other systems have insulin reservoirs of up to 300 units.
Financial impact PbR: In-tariff	The UK suppliers of the OmniPod® system (Ypsomed UK) have committed to a discount on all components which brings the mean annual cost down to a similar level as other systems.